The early clinical data from the randomized Phase 2 trial is promising but preliminary, watch for additional data expected in early 2027. The paid named-patient program in Brazil could provide non-dilutive revenue, but the company's cash runway of ~4 quarters at current burn rate means a capital raise is likely within the next 12 months. Monitor for U.S. site activations and any partnership or financing announcements.
Drug in focus
INKT drug pipeline →agenT-797
● Neutral Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- agenT-797 is not approved in any market. The most advanced program is the randomized Phase 2 ARDS trial (C-1300-02), with data expected in 2H2027. Even with positive data, additional trials and regulatory review would be needed before any potential approval, likely several years away.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $11.00entry
- T+1 · 3mo ago +2.45%α +2.65% · $11.27
- T+5 · 3mo ago +5.64%α +7.60% · $11.62
- T+20 · 2mo ago +9.09%α +10.84% · $12.00
- T+60 · 11d ago −1.09%α +4.15% · $10.88
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with cash burn slowing to $8.8M from $9.5M. The key catalyst is the randomized Phase 2 trial of agenT-797 in acute lung injury showing early positive Day 28 signals, plus the first paid named-patient access program in Brazil establishing a potential revenue stream.
Key Financial Metrics
Key Facts
- Q2 2026 net loss $3.1M ($0.62/share) vs $4.2M ($1.06/share) in Q2 2025
- Cash and equivalents $8.8M as of June 30, 2026, down from $9.5M at March 31, 2026
- First patients in randomized Phase 2 trial C-1300-02 alive at Day 28 with improved oxygenation and reduced inflammatory markers
- Launched paid named-patient access program in Brazil for agenT-797, potentially generating program revenue
- No major serious adverse events attributed to agenT-797 in initial patients
- EPS of $-0.57 beat consensus estimate of $-0.60 by 5.0%
Financial Impact
Net loss improved 26% YoY to $3.1M; cash burn of $2.1M in Q2 2026; cash runway of ~4 quarters at current burn rate
Risk Factors
- Pre-revenue clinical-stage biotech with only $8.8M cash, likely needs financing within 12 months
- Early clinical data from small number of patients in ongoing blinded trial may not be predictive of final results
- Named-patient program revenue is uncertain and not a substitute for clinical trial results or regulatory approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344397 |
Track record
21 reports on INKT
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Viewing Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers